Skip to main content
Erschienen in: Wiener klinische Wochenschrift 15-16/2015

01.08.2015 | consensus report

Lipoprotein-apheresis: Austrian consensus on indication and performance of treatment

verfasst von: Kurt Derfler, Sabine Steiner, Helmut Sinzinger

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 15-16/2015

Einloggen, um Zugang zu erhalten

Summary

The prevalence of familial disorders of lipid metabolism in Europe is higher than believed so far. In severely affected patients in whom conventional combined lipid lowering agents are insufficient to achieve target values, patients being intolerant to all the available members of the statin family as well as in patients with elevated lipoprotein(a) (100 mg/dl) and progression of atherosclerotic vascular disease, despite even normal low-density lipoproteins (LDL)-cholesterol values, lipoprotein-apheresis treatment is indicated. The Austrian Apheresis Consensus compares the inclusion criteria for patients to be treated in Austria with those from Italy, Germany, Spain, Japan, UK and the United States. The cut off level of 100 mg/dl for lipoprotein(a) is higher in Austria as compared to the aforementioned countries (50 or 60 mg/dl, respectively). The available clinical data reveal that regular weekly lipoprotein apheresis not only results in a significant lowering of the respective atherogenic lipid and lipoprotein parameters, but also in a significant decrease in clinical events and interventions. The underlying mechanisms such as non-lipid effects, side effects as well as the different available treatment principles are compared. For patients meeting the inclusion criteria, lipoprotein apheresis is a safe and effective therapy significantly reducing vascular events.
Literatur
1.
Zurück zum Zitat Heath KE, Gahan M, Whittall RA, Humphries SE. Low-density lipoprotein receptor gene (LDLR) world-wide website in familial hypercholesterolaemia: update, new features and mutation analysis. Atherosclerosis. 2001;154(1):243–6.CrossRefPubMed Heath KE, Gahan M, Whittall RA, Humphries SE. Low-density lipoprotein receptor gene (LDLR) world-wide website in familial hypercholesterolaemia: update, new features and mutation analysis. Atherosclerosis. 2001;154(1):243–6.CrossRefPubMed
2.
Zurück zum Zitat Austin MA, Hutter CM, Zimmern RL, Humphries SE. Familial hypercholesterolemia and coronary heart disease: a HuGE association review. Am J Epidemiol. 2004;160(5):421–9.CrossRefPubMed Austin MA, Hutter CM, Zimmern RL, Humphries SE. Familial hypercholesterolemia and coronary heart disease: a HuGE association review. Am J Epidemiol. 2004;160(5):421–9.CrossRefPubMed
3.
Zurück zum Zitat Goldstein JL, Brown MS. Familial hypercholesterolemia: identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol. Proc Natl Acad Sci U S A. 1973;70(10):2804–8.PubMedCentralCrossRefPubMed Goldstein JL, Brown MS. Familial hypercholesterolemia: identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol. Proc Natl Acad Sci U S A. 1973;70(10):2804–8.PubMedCentralCrossRefPubMed
4.
Zurück zum Zitat Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat. 1992;1(6):445–66.CrossRefPubMed Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat. 1992;1(6):445–66.CrossRefPubMed
5.
Zurück zum Zitat Moorjani S, Roy M, Gagne C, Davignon J, Brun D, Toussaint M, et al. Homozygous familial hypercholesterolemia among French Canadians in Quebec Province. Arteriosclerosis. 1989;9(2):211–6.CrossRefPubMed Moorjani S, Roy M, Gagne C, Davignon J, Brun D, Toussaint M, et al. Homozygous familial hypercholesterolemia among French Canadians in Quebec Province. Arteriosclerosis. 1989;9(2):211–6.CrossRefPubMed
6.
Zurück zum Zitat Kotze MJ, De Villiers WJ, Steyn K, Kriek JA, Marais AD, Langenhoven E, et al. Phenotypic variation among familial hypercholesterolemics heterozygous for either one of two Afrikaner founder LDL receptor mutations. Arterioscler Thromb. 1993;13(10):1460–8.CrossRefPubMed Kotze MJ, De Villiers WJ, Steyn K, Kriek JA, Marais AD, Langenhoven E, et al. Phenotypic variation among familial hypercholesterolemics heterozygous for either one of two Afrikaner founder LDL receptor mutations. Arterioscler Thromb. 1993;13(10):1460–8.CrossRefPubMed
7.
Zurück zum Zitat Gylling H, Aalto-Setala K, Kontula K, Miettinen TA. Serum low-density lipoprotein cholesterol level and cholesterol absorption efficiency are influenced by apolipoprotein B and E polymorphism and by the FH-Helsinki mutation of the low-density lipoprotein receptor gene in familial hypercholesterolemia. Arterioscler Thromb. 1991;11(5):1368–75.CrossRefPubMed Gylling H, Aalto-Setala K, Kontula K, Miettinen TA. Serum low-density lipoprotein cholesterol level and cholesterol absorption efficiency are influenced by apolipoprotein B and E polymorphism and by the FH-Helsinki mutation of the low-density lipoprotein receptor gene in familial hypercholesterolemia. Arterioscler Thromb. 1991;11(5):1368–75.CrossRefPubMed
8.
9.
Zurück zum Zitat Bujo H, Takahashi K, Saito Y, Maruyama T, Yamashita S, Matsuzawa Y, et al. Clinical features of familial hypercholesterolemia in Japan in a database from 1996 to 1998 by the research committee of the ministry of health, labour and welfare of Japan. J Atheroscler Thromb. 2004;11(3):146–51.CrossRefPubMed Bujo H, Takahashi K, Saito Y, Maruyama T, Yamashita S, Matsuzawa Y, et al. Clinical features of familial hypercholesterolemia in Japan in a database from 1996 to 1998 by the research committee of the ministry of health, labour and welfare of Japan. J Atheroscler Thromb. 2004;11(3):146–51.CrossRefPubMed
10.
Zurück zum Zitat Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation. 2000;101(2):207–13.CrossRefPubMed Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation. 2000;101(2):207–13.CrossRefPubMed
11.
Zurück zum Zitat Endo A, Tsujita Y, Kuroda M, Tanzawa K. Inhibition of cholesterol synthesis in vitro and in vivo by ML-236 A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Eur J Biochem. 1977;77(1):31–6.CrossRefPubMed Endo A, Tsujita Y, Kuroda M, Tanzawa K. Inhibition of cholesterol synthesis in vitro and in vivo by ML-236 A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Eur J Biochem. 1977;77(1):31–6.CrossRefPubMed
12.
Zurück zum Zitat Grundy SM. Consensus statement: Role of therapy with “statins” in patients with hypertriglyceridemia. Am J Cardiol. 1998;81(4A):1B–6B.CrossRefPubMed Grundy SM. Consensus statement: Role of therapy with “statins” in patients with hypertriglyceridemia. Am J Cardiol. 1998;81(4A):1B–6B.CrossRefPubMed
13.
Zurück zum Zitat Marais AD, Naoumova RP, Firth JC, Penny C, Neuwirth CK, Thompson GR. Decreased production of low-density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. J Lipid Res. 1997;38(10):2071–8.PubMed Marais AD, Naoumova RP, Firth JC, Penny C, Neuwirth CK, Thompson GR. Decreased production of low-density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. J Lipid Res. 1997;38(10):2071–8.PubMed
14.
Zurück zum Zitat Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess. 2007;11(14):1–160.CrossRef Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess. 2007;11(14):1–160.CrossRef
15.
Zurück zum Zitat Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL-cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81.CrossRefPubMed Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL-cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81.CrossRefPubMed
16.
Zurück zum Zitat Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DC, Liem AH, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ. 2008;337:a2423.PubMedCentralCrossRefPubMed Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DC, Liem AH, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ. 2008;337:a2423.PubMedCentralCrossRefPubMed
17.
Zurück zum Zitat Neil A, Cooper J, Betteridge J, Capps N, McDowell I, Durrington P, et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J. 2008;29(21):2625–33.PubMedCentralCrossRefPubMed Neil A, Cooper J, Betteridge J, Capps N, McDowell I, Durrington P, et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J. 2008;29(21):2625–33.PubMedCentralCrossRefPubMed
18.
Zurück zum Zitat Hunninghake D, Insull W Jr, Toth P, Davidson D, Donovan JM, Burke SK. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis. 2001;158(2):407–16.CrossRefPubMed Hunninghake D, Insull W Jr, Toth P, Davidson D, Donovan JM, Burke SK. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis. 2001;158(2):407–16.CrossRefPubMed
19.
Zurück zum Zitat Knapp HH, Schrott H, Ma P, Knopp R, Chin B, Gaziano JM, et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med. 2001;110(5):352–60.CrossRefPubMed Knapp HH, Schrott H, Ma P, Knopp R, Chin B, Gaziano JM, et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med. 2001;110(5):352–60.CrossRefPubMed
20.
Zurück zum Zitat Hamilton-Craig I, Kostner K, Colquhoun D, Woodhouse S. Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia. Vasc Health Risk Manag. 2010;6:1023–37.PubMedCentralCrossRefPubMed Hamilton-Craig I, Kostner K, Colquhoun D, Woodhouse S. Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia. Vasc Health Risk Manag. 2010;6:1023–37.PubMedCentralCrossRefPubMed
21.
Zurück zum Zitat Davidson MH, Stein EA, Bays HE, Maki KC, Doyle RT, Shalwitz RA, et al. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther. 2007;29(7):1354–67.CrossRefPubMed Davidson MH, Stein EA, Bays HE, Maki KC, Doyle RT, Shalwitz RA, et al. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther. 2007;29(7):1354–67.CrossRefPubMed
22.
Zurück zum Zitat Thompson GR. Recommendations for the use of LDL-apheresis. Atherosclerosis. 2008;198(2):247–55.CrossRefPubMed Thompson GR. Recommendations for the use of LDL-apheresis. Atherosclerosis. 2008;198(2):247–55.CrossRefPubMed
23.
Zurück zum Zitat Stefanutti C. The 2009 2nd Italian Consensus Conference on LDL-apheresis. Nutr Metab Cardiovasc Dis. 2010;20(10):761–2.CrossRefPubMed Stefanutti C. The 2009 2nd Italian Consensus Conference on LDL-apheresis. Nutr Metab Cardiovasc Dis. 2010;20(10):761–2.CrossRefPubMed
24.
Zurück zum Zitat Harada-Shiba M, Arai H, Oikawa S, Ohta T, Okada T, Okamura T, et al. Guidelines for the management of familial hypercholesterolemia. J Atheroscler Thromb. 2012;19(12):1043–60.CrossRefPubMed Harada-Shiba M, Arai H, Oikawa S, Ohta T, Okada T, Okamura T, et al. Guidelines for the management of familial hypercholesterolemia. J Atheroscler Thromb. 2012;19(12):1043–60.CrossRefPubMed
25.
Zurück zum Zitat Civiera F. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis. 2004;173(1):55–68.CrossRef Civiera F. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis. 2004;173(1):55–68.CrossRef
26.
Zurück zum Zitat Goldberg AC, Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, Robinson JG, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5 Suppl 3:S1–S8.CrossRefPubMed Goldberg AC, Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, Robinson JG, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5 Suppl 3:S1–S8.CrossRefPubMed
27.
Zurück zum Zitat Vishwanath R, Hemphill LC. Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy. J Clin Lipidol. 2014;8(1):18–28.CrossRefPubMed Vishwanath R, Hemphill LC. Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy. J Clin Lipidol. 2014;8(1):18–28.CrossRefPubMed
28.
Zurück zum Zitat Thompson GR, Catapano A, Saheb S, Atassi-Dumont M, Barbir M, Eriksson M, et al. Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe. Curr Opin Lipidol. 2010;21(6):492–8.CrossRefPubMed Thompson GR, Catapano A, Saheb S, Atassi-Dumont M, Barbir M, Eriksson M, et al. Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe. Curr Opin Lipidol. 2010;21(6):492–8.CrossRefPubMed
29.
Zurück zum Zitat Klingel R, Gohlen B, Schwarting A, Himmelsbach F, Straube R. Differential indication of lipoprotein apheresis during pregnancy. Ther Apher Dial. 2003;7(3):359–64.CrossRefPubMed Klingel R, Gohlen B, Schwarting A, Himmelsbach F, Straube R. Differential indication of lipoprotein apheresis during pregnancy. Ther Apher Dial. 2003;7(3):359–64.CrossRefPubMed
30.
Zurück zum Zitat Banyai S, Streicher J, Strobl W, Gabriel H, Gottsauner-Wolf M, Rohac M, et al. Therapeutic efficiency of lipoprotein(a) reduction by low-density lipoprotein immunoapheresis. Metabolism. 1998;47(9):1058–64.CrossRefPubMed Banyai S, Streicher J, Strobl W, Gabriel H, Gottsauner-Wolf M, Rohac M, et al. Therapeutic efficiency of lipoprotein(a) reduction by low-density lipoprotein immunoapheresis. Metabolism. 1998;47(9):1058–64.CrossRefPubMed
31.
Zurück zum Zitat Klingel R, Mausfeld P, Fassbender C, Goehlen B. Lipidfiltration-safe and effective methodology to perform lipid-apheresis. Transfus Apher Sci. 2004;30(3):245–54.CrossRefPubMed Klingel R, Mausfeld P, Fassbender C, Goehlen B. Lipidfiltration-safe and effective methodology to perform lipid-apheresis. Transfus Apher Sci. 2004;30(3):245–54.CrossRefPubMed
32.
Zurück zum Zitat Streicher J, Valent P, Schmidt H, Sengolge G, Wagner O, Strobl W, et al. Up-regulation of LDL-receptor expression by LDL-immunoapheresis in patients with familial hypercholesterolemia. J Investig Med. 1999;47(8):378–87.PubMed Streicher J, Valent P, Schmidt H, Sengolge G, Wagner O, Strobl W, et al. Up-regulation of LDL-receptor expression by LDL-immunoapheresis in patients with familial hypercholesterolemia. J Investig Med. 1999;47(8):378–87.PubMed
33.
Zurück zum Zitat Kroon AA, van’t Hof MA, Demacker PN, Stalenhoef AF. The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels. Atherosclerosis. 2000;152(2):519–26.CrossRefPubMed Kroon AA, van’t Hof MA, Demacker PN, Stalenhoef AF. The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels. Atherosclerosis. 2000;152(2):519–26.CrossRefPubMed
34.
Zurück zum Zitat Thompson GR, Barbir M, Davies D, Dobral P, Gesinde M, Livingston M, et al. Efficacy criteria and cholesterol targets for LDL-apheresis. Atherosclerosis. 2010;208(2):317–21.CrossRefPubMed Thompson GR, Barbir M, Davies D, Dobral P, Gesinde M, Livingston M, et al. Efficacy criteria and cholesterol targets for LDL-apheresis. Atherosclerosis. 2010;208(2):317–21.CrossRefPubMed
35.
Zurück zum Zitat Oguogho A, Ferlitsch A, Sinzinger H. LDL-apheresis decreases plasma levels and urinary excretion of 8-epi-PGF2alpha. Prostaglandins Leukot Essent Fatty Acids. 2000;62(4):209–16.CrossRefPubMed Oguogho A, Ferlitsch A, Sinzinger H. LDL-apheresis decreases plasma levels and urinary excretion of 8-epi-PGF2alpha. Prostaglandins Leukot Essent Fatty Acids. 2000;62(4):209–16.CrossRefPubMed
37.
Zurück zum Zitat Kurtoglu E, Ugur A, Sait Gonen M, KiSakol G. Effect of lipoprotein apheresis on oxidative stress and antioxidant status in familial hypercholesterolemic patients. Int J Artif Organs. 2003;26(11):1039–43.PubMed Kurtoglu E, Ugur A, Sait Gonen M, KiSakol G. Effect of lipoprotein apheresis on oxidative stress and antioxidant status in familial hypercholesterolemic patients. Int J Artif Organs. 2003;26(11):1039–43.PubMed
38.
Zurück zum Zitat Sinzinger H, Pirich C, Bednar J, O’Grady J. Ex-vivo and in-vivo platelet function in patients with severe hypercholesterolemia undergoing LDL-apheresis. Thromb Res. 1996;82(4):291–301.CrossRefPubMed Sinzinger H, Pirich C, Bednar J, O’Grady J. Ex-vivo and in-vivo platelet function in patients with severe hypercholesterolemia undergoing LDL-apheresis. Thromb Res. 1996;82(4):291–301.CrossRefPubMed
39.
Zurück zum Zitat Palumbo B, Cardinali L, Sinzinger H. LDL-Apheresis removes serum amyloid P and A in hypercholesterolemic patients. Thromb Res. 2000;97(6):491–4.CrossRefPubMed Palumbo B, Cardinali L, Sinzinger H. LDL-Apheresis removes serum amyloid P and A in hypercholesterolemic patients. Thromb Res. 2000;97(6):491–4.CrossRefPubMed
40.
Zurück zum Zitat Leitinger N, Pirich C, Blazek I, Endler G, Sinzinger H. Decreased susceptibility of low-density lipoproteins to in-vitro oxidation after dextran-sulfate LDL-apheresis treatment. Atherosclerosis. 1996;126(2):305–12.CrossRefPubMed Leitinger N, Pirich C, Blazek I, Endler G, Sinzinger H. Decreased susceptibility of low-density lipoproteins to in-vitro oxidation after dextran-sulfate LDL-apheresis treatment. Atherosclerosis. 1996;126(2):305–12.CrossRefPubMed
41.
Zurück zum Zitat Schmaldienst S, Banyai S, Stulnig TM, Heinz G, Jansen M, Horl WH, et al. Prospective randomised cross-over comparison of three LDL-apheresis systems in statin pretreated patients with familial hypercholesterolaemia. Atherosclerosis. 2000;151(2):493–9.CrossRefPubMed Schmaldienst S, Banyai S, Stulnig TM, Heinz G, Jansen M, Horl WH, et al. Prospective randomised cross-over comparison of three LDL-apheresis systems in statin pretreated patients with familial hypercholesterolaemia. Atherosclerosis. 2000;151(2):493–9.CrossRefPubMed
42.
Zurück zum Zitat Stefanutti C, Morozzi C, Petta A. Lipid and low-density-lipoprotein apheresis. Effects on plasma inflammatory profile and on cytokine pattern in patients with severe dyslipidemia. Cytokine. 2011;56(3):842–9.CrossRefPubMed Stefanutti C, Morozzi C, Petta A. Lipid and low-density-lipoprotein apheresis. Effects on plasma inflammatory profile and on cytokine pattern in patients with severe dyslipidemia. Cytokine. 2011;56(3):842–9.CrossRefPubMed
43.
Zurück zum Zitat Rubba P, Faccenda F, Somma SD, Gnasso A, Scarpato N, Iannuzzi A, et al. Cerebral blood flow velocity and systemic vascular resistance after acute reduction of low-density lipoprotein in familial hypercholesterolemia. Stroke. 1993;24(8):1154–61.CrossRefPubMed Rubba P, Faccenda F, Somma SD, Gnasso A, Scarpato N, Iannuzzi A, et al. Cerebral blood flow velocity and systemic vascular resistance after acute reduction of low-density lipoprotein in familial hypercholesterolemia. Stroke. 1993;24(8):1154–61.CrossRefPubMed
44.
Zurück zum Zitat Rubba P, Iannuzzi A, Postiglione A, Scarpato N, Montefusco S, Gnasso A, et al. Hemodynamic changes in the peripheral circulation after repeat low-density lipoprotein apheresis in familial hypercholesterolemia. Circulation. 1990;81(2):610–6.CrossRefPubMed Rubba P, Iannuzzi A, Postiglione A, Scarpato N, Montefusco S, Gnasso A, et al. Hemodynamic changes in the peripheral circulation after repeat low-density lipoprotein apheresis in familial hypercholesterolemia. Circulation. 1990;81(2):610–6.CrossRefPubMed
45.
Zurück zum Zitat Aengevaeren WR, Kroon AA, Stalenhoef AF, Uijen GJ, van der Werf T. Low-density lipoprotein apheresis improves regional myocardial perfusion in patients with hypercholesterolemia and extensive coronary artery disease. LDL-Apheresis Atherosclerosis Regression Study (LAARS). J Am Coll Cardiol. 1996;28(7):1696–704.CrossRefPubMed Aengevaeren WR, Kroon AA, Stalenhoef AF, Uijen GJ, van der Werf T. Low-density lipoprotein apheresis improves regional myocardial perfusion in patients with hypercholesterolemia and extensive coronary artery disease. LDL-Apheresis Atherosclerosis Regression Study (LAARS). J Am Coll Cardiol. 1996;28(7):1696–704.CrossRefPubMed
46.
Zurück zum Zitat Kitabatake A, Sato H, Hori M, Kamada T, Kubori S, Hoki N, et al. Coronary atherosclerosis reduced in patients with familial hypercholesterolemia after intensive cholesterol lowering with low-density lipoprotein-apheresis: 1-year follow-up study. The Osaka LDL-Apheresis Multicenter Trial Group. Clin Ther. 1994;16(3):416–28.PubMed Kitabatake A, Sato H, Hori M, Kamada T, Kubori S, Hoki N, et al. Coronary atherosclerosis reduced in patients with familial hypercholesterolemia after intensive cholesterol lowering with low-density lipoprotein-apheresis: 1-year follow-up study. The Osaka LDL-Apheresis Multicenter Trial Group. Clin Ther. 1994;16(3):416–28.PubMed
47.
Zurück zum Zitat Matsuzaki M, Hiramori K, Imaizumi T, Kitabatake A, Hishida H, Nomura M, et al. Intravascular ultrasound evaluation of coronary plaque regression by low-density lipoprotein-apheresis in familial hypercholesterolemia: the Low-Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART). J Am Coll Cardiol. 2002;40(2):220–7.CrossRefPubMed Matsuzaki M, Hiramori K, Imaizumi T, Kitabatake A, Hishida H, Nomura M, et al. Intravascular ultrasound evaluation of coronary plaque regression by low-density lipoprotein-apheresis in familial hypercholesterolemia: the Low-Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART). J Am Coll Cardiol. 2002;40(2):220–7.CrossRefPubMed
48.
Zurück zum Zitat Koga N, Watanabe K, Kurashige Y, Sato T, Hiroki T. Long-term effects of LDL apheresis on carotid arterial atherosclerosis in familial hypercholesterolaemic patients. J Intern Med. 1999;246(1):35–43.CrossRefPubMed Koga N, Watanabe K, Kurashige Y, Sato T, Hiroki T. Long-term effects of LDL apheresis on carotid arterial atherosclerosis in familial hypercholesterolaemic patients. J Intern Med. 1999;246(1):35–43.CrossRefPubMed
49.
Zurück zum Zitat Tsuchida H, Shigematsu H, Ishimaru S, Iwai T, Akaba N, Umezu S. Effect of low-density lipoprotein apheresis on patients with peripheral arterial disease. Peripheral Arterial Disease LDL Apheresis Multicenter Study (P-LAS). Int Angiol. 2006;25(3):287–92.PubMed Tsuchida H, Shigematsu H, Ishimaru S, Iwai T, Akaba N, Umezu S. Effect of low-density lipoprotein apheresis on patients with peripheral arterial disease. Peripheral Arterial Disease LDL Apheresis Multicenter Study (P-LAS). Int Angiol. 2006;25(3):287–92.PubMed
50.
Zurück zum Zitat Tatami R, Inoue N, Itoh H, Kishino B, Koga N, Nakashima Y, et al. Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter study. The LARS Investigators. Atherosclerosis. 1992;95(1):1–13.CrossRefPubMed Tatami R, Inoue N, Itoh H, Kishino B, Koga N, Nakashima Y, et al. Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter study. The LARS Investigators. Atherosclerosis. 1992;95(1):1–13.CrossRefPubMed
51.
Zurück zum Zitat Waidner T, Franzen D, Voelker W, Ritter M, Borberg H, Hombach V, et al. The effect of LDL apheresis on progression of coronary artery disease in patients with familial hypercholesterolemia. Results of a multicenter LDL apheresis study. Clin Investig. 1994;72(11):858–63.CrossRefPubMed Waidner T, Franzen D, Voelker W, Ritter M, Borberg H, Hombach V, et al. The effect of LDL apheresis on progression of coronary artery disease in patients with familial hypercholesterolemia. Results of a multicenter LDL apheresis study. Clin Investig. 1994;72(11):858–63.CrossRefPubMed
52.
Zurück zum Zitat Schuff-Werner P, Gohlke H, Bartmann U, Baggio G, Corti MC, Dinsenbacher A, Eisenhauer T, et al. The HELP-LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the course of coronary heart disease. The HELP-Study Group. Heparin-induced extra-corporeal LDL-precipitation. Eur J Clin Invest. 1994;24(11):724–32.CrossRefPubMed Schuff-Werner P, Gohlke H, Bartmann U, Baggio G, Corti MC, Dinsenbacher A, Eisenhauer T, et al. The HELP-LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the course of coronary heart disease. The HELP-Study Group. Heparin-induced extra-corporeal LDL-precipitation. Eur J Clin Invest. 1994;24(11):724–32.CrossRefPubMed
53.
Zurück zum Zitat Thompson GR, Maher VM, Matthews S, Kitano Y, Neuwirth C, Shortt MB, et al. Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis. Lancet. 1995;345(8953):811–6.CrossRefPubMed Thompson GR, Maher VM, Matthews S, Kitano Y, Neuwirth C, Shortt MB, et al. Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis. Lancet. 1995;345(8953):811–6.CrossRefPubMed
54.
Zurück zum Zitat Kroon AA, Aengevaeren WR, van der Werf T, Uijen GJ, Reiber JH, Bruschke AV, et al. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation. 1996;93(10):1826–35.CrossRefPubMed Kroon AA, Aengevaeren WR, van der Werf T, Uijen GJ, Reiber JH, Bruschke AV, et al. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation. 1996;93(10):1826–35.CrossRefPubMed
55.
Zurück zum Zitat Richter WO, Donner MG, Hofling B, Schwandt P. Long-term effect of low-density lipoprotein apheresis on plasma lipoproteins and coronary heart disease in native vessels and coronary bypass in severe heterozygous familial hypercholesterolemia. Metabolism. 1998;47(7):863–8.CrossRefPubMed Richter WO, Donner MG, Hofling B, Schwandt P. Long-term effect of low-density lipoprotein apheresis on plasma lipoproteins and coronary heart disease in native vessels and coronary bypass in severe heterozygous familial hypercholesterolemia. Metabolism. 1998;47(7):863–8.CrossRefPubMed
56.
Zurück zum Zitat Nishimura S, Sekiguchi M, Kano T, Ishiwata S, Nagasaki F, Nishide T, et al. Effects of intensive lipid lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan Low-density Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study (L-CAPS). Atherosclerosis. 1999;144(2):409–17.CrossRefPubMed Nishimura S, Sekiguchi M, Kano T, Ishiwata S, Nagasaki F, Nishide T, et al. Effects of intensive lipid lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan Low-density Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study (L-CAPS). Atherosclerosis. 1999;144(2):409–17.CrossRefPubMed
57.
Zurück zum Zitat Palcoux JB, Atassi-Dumont M, Lefevre P, Hequet O, Schlienger JL, Brignon P, et al. Low-density lipoprotein apheresis in children with familial hypercholesterolemia: follow-up to 21 years. Ther Apher Dial. 2008;12(3):195–201.CrossRefPubMed Palcoux JB, Atassi-Dumont M, Lefevre P, Hequet O, Schlienger JL, Brignon P, et al. Low-density lipoprotein apheresis in children with familial hypercholesterolemia: follow-up to 21 years. Ther Apher Dial. 2008;12(3):195–201.CrossRefPubMed
58.
Zurück zum Zitat Hudgins LC, Kleinman B, Scheuer A, White S, Gordon BR. Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia. Am J Cardiol. 2008;102(9):1199–204.CrossRefPubMed Hudgins LC, Kleinman B, Scheuer A, White S, Gordon BR. Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia. Am J Cardiol. 2008;102(9):1199–204.CrossRefPubMed
59.
Zurück zum Zitat Kolansky DM, Cuchel M, Clark BJ, Paridon S, McCrindle BW, Wiegers SE, et al. Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia. Am J Cardiol. 2008;102(11):1438–43.CrossRefPubMed Kolansky DM, Cuchel M, Clark BJ, Paridon S, McCrindle BW, Wiegers SE, et al. Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia. Am J Cardiol. 2008;102(11):1438–43.CrossRefPubMed
60.
Zurück zum Zitat Mabuchi H, Koizumi J, Shimizu M, Kajinami K, Miyamoto S, Ueda K, et al. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am J Cardiol. 1998;82(12):1489–95.CrossRefPubMed Mabuchi H, Koizumi J, Shimizu M, Kajinami K, Miyamoto S, Ueda K, et al. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am J Cardiol. 1998;82(12):1489–95.CrossRefPubMed
61.
Zurück zum Zitat Koziolek MJ, Hennig U, Zapf A, Bramlage C, Grupp C, Armstrong VW, et al. Retrospective analysis of long-term lipid apheresis at a single center. Ther Apher Dial. 2010;14(2):143–52.CrossRefPubMed Koziolek MJ, Hennig U, Zapf A, Bramlage C, Grupp C, Armstrong VW, et al. Retrospective analysis of long-term lipid apheresis at a single center. Ther Apher Dial. 2010;14(2):143–52.CrossRefPubMed
62.
Zurück zum Zitat Jaeger BR, Richter Y, Nagel D, Heigl F, Vogt A, Roeseler E, et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med. 2009;6(3):229–39.CrossRefPubMed Jaeger BR, Richter Y, Nagel D, Heigl F, Vogt A, Roeseler E, et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med. 2009;6(3):229–39.CrossRefPubMed
63.
Zurück zum Zitat Thompson GR. The evidence-base for the efficacy of lipoprotein apheresis in combating cardiovascular disease. Atheroscler Suppl. 2013;14(1):67–70.CrossRefPubMed Thompson GR. The evidence-base for the efficacy of lipoprotein apheresis in combating cardiovascular disease. Atheroscler Suppl. 2013;14(1):67–70.CrossRefPubMed
64.
Zurück zum Zitat Schwartz J, Winters JL, Padmanabhan A, Balogun RA, Delaney M, Linenberger ML, et al. Guidelines on the use of therapeutic apheresis in clinical practice- evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher. 2013;28(3):145–284.CrossRefPubMed Schwartz J, Winters JL, Padmanabhan A, Balogun RA, Delaney M, Linenberger ML, et al. Guidelines on the use of therapeutic apheresis in clinical practice- evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher. 2013;28(3):145–284.CrossRefPubMed
65.
Zurück zum Zitat Berthold HK, Descamps OS, Gouni-Berthold I. Lipoprotein apheresis in isolated hyperlipoproteinemia (a): a validated treatment or an illusion of validity? Eur J Clin Invest. 2013;43(1):108–12.CrossRefPubMed Berthold HK, Descamps OS, Gouni-Berthold I. Lipoprotein apheresis in isolated hyperlipoproteinemia (a): a validated treatment or an illusion of validity? Eur J Clin Invest. 2013;43(1):108–12.CrossRefPubMed
66.
Zurück zum Zitat Thompson GR, Lowenthal R, Myant NB. Plasma exchange in the management of homozygous familial hypercholesterolaemia. The Lancet. 1975;1(7918):1208–11.CrossRef Thompson GR, Lowenthal R, Myant NB. Plasma exchange in the management of homozygous familial hypercholesterolaemia. The Lancet. 1975;1(7918):1208–11.CrossRef
67.
Zurück zum Zitat Richter WO, Jacob BG, Ritter MM, Suhler K, Vierneisel K, Schwandt P. Three-year treatment of familial heterozygous hypercholesterolemia by extracorporeal low-density lipoprotein immunoadsorption with polyclonal apolipoprotein B antibodies. Metabolism. 1993;42(7):888–94.CrossRefPubMed Richter WO, Jacob BG, Ritter MM, Suhler K, Vierneisel K, Schwandt P. Three-year treatment of familial heterozygous hypercholesterolemia by extracorporeal low-density lipoprotein immunoadsorption with polyclonal apolipoprotein B antibodies. Metabolism. 1993;42(7):888–94.CrossRefPubMed
68.
Zurück zum Zitat Yokoyama S, Hayashi R, Satani M, Yamamoto A. Selective removal of low-density lipoprotein by plasmapheresis in familial hypercholesterolemia. Arteriosclerosis. 1985;5(6):613–22.CrossRefPubMed Yokoyama S, Hayashi R, Satani M, Yamamoto A. Selective removal of low-density lipoprotein by plasmapheresis in familial hypercholesterolemia. Arteriosclerosis. 1985;5(6):613–22.CrossRefPubMed
69.
Zurück zum Zitat Eisenhauer T, Armstrong VW, Wieland H, Fuchs C, Scheler F, Seidel D. Selective removal of low density lipoproteins (LDL) by precipitation at low pH: first clinical application of the HELP system. Klin Wochenschr. 1987;65(4):161–8.CrossRefPubMed Eisenhauer T, Armstrong VW, Wieland H, Fuchs C, Scheler F, Seidel D. Selective removal of low density lipoproteins (LDL) by precipitation at low pH: first clinical application of the HELP system. Klin Wochenschr. 1987;65(4):161–8.CrossRefPubMed
70.
Zurück zum Zitat Bosch T, Schmidt B, Blumenstein M, Gurland HJ. Lipid apheresis by hemoperfusion: in vitro efficacy and ex vivo biocompatibility of a new low-density lipoprotein adsorber compatible with human whole blood. Artif Organs. 1993;17(7):640–52.CrossRefPubMed Bosch T, Schmidt B, Blumenstein M, Gurland HJ. Lipid apheresis by hemoperfusion: in vitro efficacy and ex vivo biocompatibility of a new low-density lipoprotein adsorber compatible with human whole blood. Artif Organs. 1993;17(7):640–52.CrossRefPubMed
72.
Zurück zum Zitat Thiery J, Seidel D. Safety and effectiveness of long-term LDL-apheresis in patients at high risk. Curr Opin Lipidol. 1998;9(6):521–6.CrossRefPubMed Thiery J, Seidel D. Safety and effectiveness of long-term LDL-apheresis in patients at high risk. Curr Opin Lipidol. 1998;9(6):521–6.CrossRefPubMed
73.
Zurück zum Zitat Bambauer R, Schiel R, Latza R. Low-density lipoprotein apheresis: an overview. Ther Apher Dial. 2003;7(4):382–90.CrossRefPubMed Bambauer R, Schiel R, Latza R. Low-density lipoprotein apheresis: an overview. Ther Apher Dial. 2003;7(4):382–90.CrossRefPubMed
74.
Zurück zum Zitat Koga N. Efficacy and safety measures for low-density lipoprotein apheresis treatment using dextran sulfate cellulose columns. Ther Apher. 1999;3(2):155–60.CrossRefPubMed Koga N. Efficacy and safety measures for low-density lipoprotein apheresis treatment using dextran sulfate cellulose columns. Ther Apher. 1999;3(2):155–60.CrossRefPubMed
75.
Zurück zum Zitat Kojima S, Ogi M, Yoshitomi Y, Kuramochi M, Ikeda J, Naganawa M, et al. Changes in bradykinin and prostaglandins plasma levels during dextran-sulfate low-density-lipoprotein apheresis. Int J Artif Organs. 1997;20(3):178–83.PubMed Kojima S, Ogi M, Yoshitomi Y, Kuramochi M, Ikeda J, Naganawa M, et al. Changes in bradykinin and prostaglandins plasma levels during dextran-sulfate low-density-lipoprotein apheresis. Int J Artif Organs. 1997;20(3):178–83.PubMed
76.
Zurück zum Zitat Krieter DH, Steinke J, Kerkhoff M, Fink E, Lemke HD, Zingler C, et al. Contact activation in low-density lipoprotein apheresis systems. Artif Organs. 2005;29(1):47–52.CrossRefPubMed Krieter DH, Steinke J, Kerkhoff M, Fink E, Lemke HD, Zingler C, et al. Contact activation in low-density lipoprotein apheresis systems. Artif Organs. 2005;29(1):47–52.CrossRefPubMed
77.
Zurück zum Zitat Sinzinger H, Bednar J, Granegger S, Blazek I, Peskar BA. LDL-apheresis and concomitant ACE-inhibitor therapy. Atherosclerosis. 1994;105(1):115–6.CrossRefPubMed Sinzinger H, Bednar J, Granegger S, Blazek I, Peskar BA. LDL-apheresis and concomitant ACE-inhibitor therapy. Atherosclerosis. 1994;105(1):115–6.CrossRefPubMed
78.
Zurück zum Zitat Sinzinger H, Chehne F, Ferlitsch A, Oguogho A. Angiotensin receptor antagonists during dextran sulfate LDL-apheresis are safe. Thromb Res. 2000;100(1):43–6.CrossRefPubMed Sinzinger H, Chehne F, Ferlitsch A, Oguogho A. Angiotensin receptor antagonists during dextran sulfate LDL-apheresis are safe. Thromb Res. 2000;100(1):43–6.CrossRefPubMed
Metadaten
Titel
Lipoprotein-apheresis: Austrian consensus on indication and performance of treatment
verfasst von
Kurt Derfler
Sabine Steiner
Helmut Sinzinger
Publikationsdatum
01.08.2015
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 15-16/2015
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-015-0833-4

Weitere Artikel der Ausgabe 15-16/2015

Wiener klinische Wochenschrift 15-16/2015 Zur Ausgabe

mitteilungen der gesellschaft der ärzte in wien

Veranstaltungen